Skip to content
sellWeak cluster of 210b5-1 plan

Marshall Urist sold $236k of RPRX

EVP, Research & Investments at Royalty Pharma plc. 4,126 shares at an average of $57.10, traded Oct 5, 2026, filed Oct 5, 2026.

Warning score
36
Value
$236k
4,126 shares
Holdings after
0
-100% from before
From 52-week low
+63%
low $34.77, close $56.66
From 52-week high
-11%
high $63.96, as of Oct 5, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $236k at market
    +13
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RPRXOct 9, 2026 · close 56.93
Since filing Oct 5, 2026: +0.5%SPY +0.5% · excess -0.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001838139-26-000028, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 5, 2026SOpen-market sale
Class A Ordinary Shares10b5-1
-4,126$57.10$236k07 d ago

Related signals

Other insiders at Royalty Pharma plc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
RPRXsell 210b5-1
Royalty Pharma plc
Marshall Urist
EVP, Research & Investments
$239k
4,126 shares
-50%
43Moderate
RPRXsell 210b5-1
Royalty Pharma plc
Christopher Hite
EVP & Chairman, Partnering
$5.9M
100,000 shares
-27%
45Moderate
RPRXsell
Royalty Pharma plc
Gregory Norden
director
$1.2M
33,500 shares
-15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.